AI assistant
Lupin Ltd — Capital/Financing Update 2026
Mar 19, 2026
61031_rns_2026-03-19_2599e6f9-0893-41b6-9d25-5f4a70c0caad.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [84 x 99] intentionally omitted <==
March 19, 2026
National Stock Exchange of India Limited
BSE Limited
Exchange Plaza, P. J. Towers, Dalal Street, Bandra Kurla Complex, Mumbai Samachar Marg, Bandra (East), Mumbai - 400 001 Mumbai - 400 051 Symbol: LUPIN Scrip Code: Equity - 500257
Subject: Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
Dear Sir/Madam,
We are pleased to enclose a Press Release titled “Lupin Manufacturing Solutions Announces Expansion of Manufacturing Facility at Dabhasa, India”.
The same is for your information and dissemination.
Thanking you,
For LUPIN LIMITED
Digitally signed by Amit Kumar Amit Kumar Gupta Gupta Date: 2026.03.19 08:03:40 +05'30'
AMIT KUMAR GUPTA COMPANY SECRETARY & COMPLIANCE OFFICER (ACS -15754)
Encl.: a/a.
LUPIN LIMITED
Registered Office: 3[rd] Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323.
Corporate Identity Number: L24100MH1983PLC029442 [email protected] | www.lupin.com
Press Release
==> picture [68 x 69] intentionally omitted <==
==> picture [425 x 9] intentionally omitted <==
----- Start of picture text -----
BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPCIN
----- End of picture text -----
Lupin Manufacturing Solutions Announces Expansion of Manufacturing Facility at Dabhasa, India
Strategic expansion strengthens complex development and manufacturing capabilities
Mumbai, March 19, 2026: Lupin Manufacturing Solutions (LMS), a global CRDMO and subsidiary of global pharma major Lupin Limited (Lupin), today announced a strategic expansion of its Dabhasa manufacturing facility, marking a significant step toward scaling its peptide building-blocks platform and CRDMO capabilities.
The expanded infrastructure features a new block to enhance existing CRDMO capabilities supported by dedicated peptide manufacturing capacity across two additional specialized units. These upgrades will enable advanced development and flexible manufacturing, supporting complex therapeutics and meeting global demand for advanced pharmaceutical solutions.
Dr. Abdelaziz Toumi, Chief Executive Officer, Lupin Manufacturing Solutions, said, “As pharmaceutical innovation increasingly shifts toward complex modalities, building deep capabilities and execution excellence has become critical. This expansion underscores our commitment to building advanced, scalable capabilities that support complex development programs and reinforce our role in the global peptide ecosystem, enabling meaningful partnerships with innovators worldwide.”
With global drug development increasingly defined by molecular complexity, such as peptides and biologic ADCs, this expansion reinforces LMS’s capability to consistently supply high-quality peptide building blocks, including protected amino acids.
About Lupin Manufacturing Solutions
Lupin Manufacturing Solutions Limited, a wholly owned subsidiary of Lupin Limited, is a leading manufacturer of Active Pharmaceutical Ingredients (APIs) and a global Contract Development and Manufacturing Organization (CDMO) offering standalone & integrated solutions across drug substances, complex chemistry, drug product, and advanced modalities, including ADCs and peptides. Leveraging Lupin’s legacy of scientific rigor and regulatory expertise, LMS supports biopharma innovators from early development to commercial scale. With state-of-the-art facilities, a client-first approach, and a team of 250+ scientists, LMS accelerates the path to market for transformative therapies.
For more details, visit https://www.lmscdmo.com or write to us at [email protected]
Page 1 of 2
Press Release
==> picture [68 x 69] intentionally omitted <==
BSE: 500257
NSE: LUPIN
REUTERS: LUPIN.BO
BLOOMBERG: LPCIN
About Lupin
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 24,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
To know more, visit www.lupin.com or follow us on LinkedIn https://www.linkedin.com/company/lupin
For further information or queries, please contact: Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications, Lupin [email protected]
Sachin Mangale
Global Marketing Head, Lupin Manufacturing Solutions (LMS) [email protected]
Page 2 of 2